argenx NV ADR (ARGX)vsMacroGenics Inc (MGNX)
ARGX
argenx NV ADR
$891.32
+5.82%
HEALTHCARE · Cap: $55.09B
MGNX
MacroGenics Inc
$3.91
-8.00%
HEALTHCARE · Cap: $246.63M
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 2919% more annual revenue ($4.74B vs $157.08M). ARGX leads profitability with a 31.4% profit margin vs -44.8%. MGNX appears more attractively valued with a PEG of 0.01. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
MGNX
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+62.4%
Fair Value
$2217.64
Current Price
$891.32
$1326.32 discount
Intrinsic value data unavailable for MGNX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 30.0%
Revenue surging 62.6% year-over-year
Earnings expanding 114.0% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Growing faster than its price suggests
Revenue surging 57.5% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 188.4x book value
Trading at 11.8x book value
Smaller company, higher risk/reward
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 31.4% and operating margin at 30.0%. Revenue growth of 62.6% demonstrates continued momentum.
Bull Case : MGNX
The strongest argument for MGNX centers on PEG Ratio, Revenue Growth. Revenue growth of 57.5% demonstrates continued momentum. PEG of 0.01 suggests the stock is reasonably priced for its growth.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : MGNX
The primary concerns for MGNX are Price/Book, Market Cap, Debt/Equity. Debt-to-equity of 1.72 is elevated, increasing financial risk.
Key Dynamics to Monitor
ARGX profiles as a growth stock while MGNX is a hypergrowth play — different risk/reward profiles.
MGNX carries more volatility with a beta of 1.08 — expect wider price swings.
ARGX is growing revenue faster at 62.6% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (73/100 vs 42/100), backed by strong 31.4% margins and 62.6% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
MacroGenics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapies to treat cancer in the United States. The company is headquartered in Rockville, Maryland.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?